Lilly Novos bet on heart disease starts to take shape and 2024 could be a pivotal year for their GLP1s Endpoints News

At long last, Eli Lilly has found success in its decades-long effort to develop a treatment for Alzheimer’s disease. The company announced Wednesday morning that its experimental drug, donanemab, slowed…

Grail’s vision is simple but bold. The blood testing company has long held that people are often diagnosed with cancer too late. If seemingly healthy people were screened for early…

The next wave of gene editing technology could come from bacteria living in Antarctic lakes, coal mines or even dog saliva, and those are just a few of the odd…